UCB Stock Analysis: UCB | BR
Biotechnology | BR, Belgium | Market Cap: 39.429m EUR | 12M Return: -20.3% | BE0003739530 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 51.7M
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
UCB SA is a Belgian biopharmaceutical company founded in 1925 and headquartered in Brussels, specializing in treatments for neurology and immunology diseases across global markets. The company markets a diverse portfolio of established brands including Cimzia (for autoimmune conditions such as rheumatoid arthritis and Crohns disease), Vimpat, Keppra, and Briviact for epilepsy, Neupro for Parkinsons disease and restless legs syndrome, and consumer allergy products Zyrtec and Xyzal. UCB also markets newer therapies such as Evenity for postmenopausal osteoporosis, Fintepla for severe pediatric epilepsies, and RYSTIGGO and ZILBRYSQ for generalized myasthenia gravis, while pursuing a pipeline that includes candidates for Alzheimers disease, systemic lupus erythematosus, and atopic dermatitis. Beyond branded pharmaceuticals, the company engages in contract manufacturing activities.
As a large-cap biopharmaceutical firm, UCB operates in a sector characterized by extended product development cycles, heavy reliance on patent protection, and significant investment in research and development to sustain its therapeutic franchises. Its dual focus on neurology and immunology places it in two of the more innovation-intensive segments of the pharmaceutical industry, where unmet medical needs typically support premium pricing for novel therapies.
- Bimzelx uptake accelerates across psoriasis and arthritis indications
- Vimpat generic erosion pressures core epilepsy franchise revenue
- Bepranemab Alzheimers Phase 3 readout pivotal pipeline catalyst
| Net Income: 2.19b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -0.34 > 1.0 |
| NWC/Revenue: 10.83% < 20% (prev 20.30%; Δ -9.47% < -1%) |
| CFO/TA 0.09 > 3% & CFO 1.89b > Net Income 2.19b |
| Net Debt (3.00b) to EBITDA (3.29b): 0.91 < 3 |
| Current Ratio: 1.20 > 1.5 & < 3 |
| Outstanding Shares: last quarter (190.0m) vs 12m ago -2.57% < -2% |
| Gross Margin: 76.23% > 18% (prev 71.69%; Δ 4.55% > 0.5%) |
| Asset Turnover: 45.08% > 50% (prev 39.84%; Δ 5.23% > 0%) |
| Interest Coverage Ratio: 15.39 > 6 (EBIT TTM 2.66b / Interest Expense TTM 173.0m) |
| A: 0.04 (Total Current Assets 5.46b - Total Current Liabilities 4.54b) / Total Assets 20.6b |
| B: 0.45 (Retained Earnings 9.29b / Total Assets 20.6b) |
| C: 0.14 (EBIT TTM 2.66b / Avg Total Assets 18.9b) |
| D: 1.30 (Book Value of Equity 11.7b / Total Liabilities 8.98b) |
| Altman-Z'' = 4.07 = AA |
| DSRI: 1.12 (Receivables 2.58b/1.85b, Revenue 8.52b/6.85b) |
| GMI: 0.94 (GM 71.69% / 76.23%) |
| AQI: 1.08 (AQ_t 0.63 / AQ_t-1 0.59) |
| SGI: 1.24 (Revenue 8.52b / 6.85b) |
| TATA: 0.01 (NI 2.19b - CFO 1.89b) / TA 20.6b) |
| Beneish M = -2.75 (Cap -4..+1) = A |
As of October 06, 2026, the stock is trading at EUR 200.90 with a total of 159,633 shares traded. Over the past week, the price has changed by -5.46%, over one month by -4.47%, over three months by -21.03% and over the past year by -20.30%.
Current recommended Stop Loss: 193.20 (which is 3.8% or 1.4 ATR below the current price).
UCB has no consensus analysts rating.
P/E Trailing = 18.2524
P/E Forward = 15.456
P/S = 4.6256
P/B = 3.4618
P/EG = 1.1112
Revenue TTM = 8.52b EUR
EBIT TTM = 2.66b EUR
EBITDA TTM = 3.29b EUR
Long Term Debt = 3.23b EUR (from longTermDebt, last quarter)
Short Term Debt = 217.0m EUR (from shortTermDebt, last quarter)
Debt = 3.80b EUR (from shortLongTermDebtTotal, last quarter) + Leases 209.0m
Net Debt = 3.00b EUR (calculated: Debt 3.80b - CCE 797.0m)
Enterprise Value = 42.4b EUR (39.4b + Debt 3.80b - CCE 797.0m)
Interest Coverage Ratio = 15.39 (Ebit TTM 2.66b / Interest Expense TTM 173.0m)
EV/FCF = 28.44x (Enterprise Value 42.4b / FCF TTM 1.49b)
FCF Yield = 3.52% (FCF TTM 1.49b / Enterprise Value 42.4b)
FCF Margin = 17.50% (FCF TTM 1.49b / Revenue TTM 8.52b)
Net Margin = 25.74% (Net Income TTM 2.19b / Revenue TTM 8.52b)
Gross Margin = 76.23% ((Revenue TTM 8.52b - Cost of Revenue TTM 2.03b) / Revenue TTM)
Gross Margin QoQ = 77.56% (prev 74.89%)
Tobins Q-Ratio = 2.06 (Enterprise Value 42.4b / Total Assets 20.6b)
Interest Expense / Debt = 4.56% (Interest Expense 173.0m / Debt 3.80b)
Taxrate = 13.42% (340.0m / 2.53b)
NOPAT = 2.30b (EBIT 2.66b * (1 - 13.42%))
Current Ratio = 1.20 (Total Current Assets 5.46b / Total Current Liabilities 4.54b)
Debt / Equity = 0.33 (Debt 3.80b / totalStockholderEquity, last quarter 11.7b)
Debt / EBITDA = 0.91 (Net Debt 3.00b / EBITDA 3.29b)
Debt / FCF = 2.01 (Net Debt 3.00b / FCF TTM 1.49b)
Total Stockholder Equity = 10.6b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.60% (Net Income 2.19b / Total Assets 20.6b)
RoE = 20.78% (Net Income TTM 2.19b / Total Stockholder Equity 10.6b)
RoCE = 19.31% (EBIT 2.66b / Capital Employed (Equity 10.6b + L.T.Debt 3.23b))
RoIC = 14.51% (NOPAT 2.30b / Invested Capital 15.9b)
WACC = 6.33% (E(39.4b)/V(43.2b) * Re(6.56%) + D(3.80b)/V(43.2b) * Rd(4.56%) * (1-Tc(0.13)))
Discount Rate = 6.56% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -42.81 | Cagr: -0.90%
[DCF] Terminal Value 77.92% ; FCFF base≈1.42b ; Y1≈1.62b ; Y5≈2.37b
[DCF] Fair Price = 171.1 (EV 35.6b - Net Debt 3.00b = Equity 32.6b / Shares 190.7m; r=8.35% [WACC [floored]]; 5y FCF grow 14.68% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 99.32 | Revenue CAGR: 22.69% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=11.69 | Chg30d=+0.15% | Revisions=+30% | GrowthEPS=+17.0% | GrowthRev=+12.2%
EPS next Year (2027-12-31): EPS=13.79 | Chg30d=-0.92% | Revisions=-22% | GrowthEPS=+17.9% | GrowthRev=+10.8%
[Analyst] Revisions Ratio: +6% (up=7, down=6)